|4Jun 27, 4:45 PM ET

Aberdare Management Company, LLC 4

4 · Kezar Life Sciences, Inc. · Filed Jun 27, 2018

Insider Transaction Report

Form 4
Period: 2018-06-25
Transactions
  • Conversion

    Series B Convertible Preferred Stock

    2018-06-2531,4810 total
    Common Stock (31,481 underlying)
  • Conversion

    Common Stock

    2018-06-25+105,162105,162 total
  • Conversion

    Common Stock

    2018-06-25+31,481136,643 total
  • Conversion

    Series A Convertible Preferred Stock

    2018-06-25105,1620 total
    Common Stock (105,162 underlying)
Footnotes (2)
  • [F1]Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock was convertible at any time, at the option of the holder, into Common Stock, on a one-for-one basis, had no expiration date and converted into shares of Common Stock upon the closing of the Issuer's initial public offering.
  • [F2]The members of Aberdare Management Company, LLC are Paul H. Klingenstein and Kathleen R. Bole.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION